Asthma Management Handbook

Review and finalisation

Guidelines Committee review

In addition to monitoring development of content by working groups during the development process, the Guideline Committee reviews the full draft of the Handbook before each update is finalised.

The main remit of this review is to ensure consistency across sections, also noting gaps or unnecessary duplication, as well as checking all content section-by-section.

Stakeholder review

For each major edition, selected external stakeholder organisations are invited to review the draft Handbook and submit comment. The invitation includes log-in details for the Handbook website and a submission form. The stakeholders are given a month to review the Handbook and make their submission.

Around 25 organisations are invited to review. These include:

  • National Asthma Council Australia member bodies
  • Colleges/associations of relevant health professions
  • Other stakeholder organisations including patient advocacy organisation Asthma Australia
  • Pharmaceutical companies with a respiratory interest

Table. Stakeholder bodies invited to review the draft Handbook v2.0

Member organisations and other health bodies:
  • Asthma Australia
  • Asthma Foundation NT
  • Asthma WA
  • Australasian College of Emergency Medicine
  • Australasian Society of Clinical Immunology and Allergy
  • Australian and New Zealand Society of Respiratory Science
  • Australian College of Nursing
  • Australian College of Rural and Remote Medicine
  • Australian Primary Care Nurses Association
  • Centre of Excellence in Severe Asthma
  • Consumers Health Forum of Australia
  • Generic and Biosimilar Medicines Association
  • Lung Foundation Australia
  • Lung Health Research Centre
  • Medicines Australia
  • National Aboriginal Community Controlled Health Organisation
  • NPS MedicineWise
  • Pharmaceutical Society of Australia
  • Pharmacy Guild of Australia
  • Royal Australian College of General Practitioners
  • Society of Hospital Pharmacists Australia
  • Thoracic Society of Australia and New Zealand
Pharmaceutical companies:
  • A. Menarini Australia
  • AstraZeneca Australia
  • Boehringer IngelheimĀ 
  • Cipla Australia
  • GlaxoSmithKline Australia
  • Mundipharma
  • Mylan Health
  • Novartis Pharmaceuticals Australia
  • Seqirus
  • Stallergenes Australia
  • Takeda Pharmaceuticals Australia
  • Teva Pharma Australia

Asset ID: 123


Each submission is considered by the Secretariat and Guidelines Committee during the finalisation phase of the Handbook’s development.

External expert review

For each major edition, independent experts are asked to review the full draft Handbook online during the consultation period. 

No reviewers had been involved in the development of the draft Handbook.


All feedback received during the review phase is aggregated by the Secretatriat for the Guidelines Committee. The Guidelines Committee consider and resolve all issues prior to finalising and approving the final content for publication.